Condition: B-cell Lymphoma · Non-Hodgkin Lymphoma · B-cell Malignancy · Sponsor: CRISPR Therapeutics AG
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX112™ in subjects with relapsed or refractory B-cell malignancies.
This description comes directly from the study's public registry record.
Clinical Trials · +1 (877) 214-4634 · MedicalAffairs@crisprtx.com
Always discuss trial participation with your own doctor first.
| University of Kansas | Westwood, Kansas, United States | Recruiting |
| Washington University | St Louis, Missouri, United States | Recruiting |
| SCRI | San Antonio, Texas, United States | Recruiting |
| University of Utah | Salt Lake City, Utah, United States | Recruiting |
| Royal Prince Alfred | Camperdown, New South Wales, Australia | Recruiting |
| Alfred Health | Melbourne, Victoria, Australia | Recruiting |
| Sir Charles Gairdner Hospital | Nedlands, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05643742